drug presentation slideshare

Pharmacology education for healthcare professionals

Cancer chemotherapy: PPT presentations

The PowerPoint files in this posts have been shared by R. Senthil Kumar M.D. ,  Dean of Basic Sciences and Pharmacology Professor at St. Matthew’s University School of Medicine. If you are interested in contributing to this blog, just send an e-mail to [email protected]

PPT 1: Introduction to cancer chemotherapy

Download PPT file: Cancer Chemotherapy 1

• Etiopathology.
• Characteristics of cancer cells.
• The Goal of cancer treatments.
• Major approaches to therapy of cancers.
• Cell cycle and cancer chemotherapy.
• Cell cycle specific and cell cycle non-specific agents.
• Log kill hypothesis.
• Advantages of combination chemotherapy.
• Resistance to cytotoxic drugs ( P-glycoprotein ).
• Mechanisms of resistance to anticancer drugs.
• Adverse drug reactions of antineoplastic drugs in humans.
• Distinctive toxicities in some anticancer drugs.
• Prevention or management of induced toxicities.
• Anticancer drugs chart.

PPT 2: Anticancer drugs

Download PPT file: Cancer Chemotherapy 2

• Classification of anticancer drugs.
• Alkylating agents: mechanism of action.
• Alkylating agents indications.
• Cyclophosphamide: mechanisms of resistance,clinical uses and adverse drug reactions.
• Characteristics of: Cisplatin, procarbazine.
• Antimetabolites: mechanism of action, classification.
• Methotrexate: mechanisms of resistance, ADR.
• Leucovorin rescue, 6-Mercaptopurine,6-MP and allopurinol, Cytarabine, 5-fluorouracil.
• Plant alkaloids.
• Vinka alkaloids (Vinblastine and vincristine): ADR and mechanism of action.
• Etoposide and teniposide.
• Topoisomerase inhibitors.
• Paclitaxel and decetaxel.
• Anticancer antibiotics.
• Doxorubicin: ADR.
• Hormonal agents: glucocorticoids, tamoxifen.
• GnRH analogs for prostate cancer : leuprolide, gosarelin and naferelin.
• Aromatase inhibitors.
• Miscellaneous agents: asparaginase, imatinib , interferons and monoclonal antibodies .Trastuzumab
• FDA approved monoclonal antibodies used to treat cancer.
• Treatment of specific cancers.

Most of the figures used in this post are courtesy by Lippincott Williams and Wilkins and Mc Graw Hill Medical.

About the author

R. Senthil Kumar M.D is Dean of Basic Sciences and Associate Professor of Pharmacology & Clinical Therapeutics at St. Matthew’s University, School of Medicine , Cayman Islands.

Dr. Kumar has been distinguished with numerous awards, some of them include:

• 2006 and 2007 Prestigious Dean’s Award for teaching quality and student performance.
• 2007 and 2008 Golden Apple Award for best teacher, awarded by the American Medical Students Association – AMSA- ·
• 2007 Student Government Association Faculty Recognition Award for superior teaching and motivational abilities.

Home Collections Special Days Drugs And Substance Abuse PowerPoint Presentation

Free - Drugs and Substance Abuse PPT Presentation and Google Slides

Drugs And Substance Abuse Presentation Slide

Drug and substance abuse is a serious public health problem that affects millions of people worldwide. It refers to the use of drugs or other harmful substances in a way that leads to physical, mental, and social problems. Substance abuse can cause addiction, overdose, and long-term health problems. Commonly abused substances include alcohol, tobacco, prescription drugs, and illicit drugs like cocaine and heroin. Prevention and treatment programs are available to help individuals overcome drug addiction and lead healthy, drug-free lives. By using our template, you can convey your message in a clear and concise manner.

Features of the template:

• 100 % customizable template and easy to download. 
• Template are available in different nodes & colors.
• The template is contained in 16:9 and 4:3 format.
• Easy to change the template colors quickly.
• Highly compatible with PowerPoint and google slides.
• Combat drug abuse with our informative and impactful Drugs and Substance Abuse template.
• special days
• International Day Against Drug Abuse
• Against Drug Abuse Day
• Drugs And Substance Abuse
• Against Drug Abuse June 26
• Happy International Day Against Drug Abuse
• Celebrate International Day Against Drug Abuse
• Google Slides

655+ Templates

Valentines day

69+ Templates

39+ Templates

349+ Templates

111+ Templates

Black Friday

67+ Templates

473+ Templates

159+ Templates

Cyber Monday

42+ Templates

You May Also Like These PowerPoint Templates

DRUG DOSING IN PEDIATRIC PATIENTS

Nov 07, 2019

1.17k likes | 3.39k Views

DRUG DOSING IN PEDIATRIC PATIENTS. Dr S Sirisha DEPARTMENT OF PHARMACY PRACTICE. INTRODUCTION. Better understanding of various physiological variables that are regulating the fate of the drug is important to improve both safety and efficacy of drug therapy

Share Presentation

• fraction unbound
• drug absorption
• approaches adult values
• binding protein concentration infant

Presentation Transcript

DRUG DOSING IN PEDIATRIC PATIENTS Dr S Sirisha DEPARTMENT OF PHARMACY PRACTICE

INTRODUCTION • Better understanding of various physiological variables that are regulating the fate of the drug is important to improve both safety and efficacy of drug therapy • Pediatric patients show such physiological variability and so it is important to select an appropriate dose for a pediatric patient • Here, the organs are not matured • The development of organs continue until at least to the age of 12 years • Pediatric patients were always considered in the past for treatment as MINI ADULTS

INTRODUCTION… • Classification of pediatric patients: • Preterm Neonate (Preterm Newborn Infant) (<37 weeks gestation) • Neonate (Newborn Infant ) (Birth To 27 Days) • Infant & Toddlers (28 Days To 23 Months) • Young Child (2 To 5 Years) • Older Child (6 To 11 Years) • Adolescent (12 To 18 Years) • The Adult (>18 Years)

INTRODUCTION… • The practice of scaling adult drug doses to infants and children based on BW or BSA does not account for the developmental changes that affect drug pharmacokinetics or target tissue and organ sensitivity to the drug • In fact, this dosing practice has resulted in therapeutic tragedies that illustrate the importance of understanding the effects of ontogeny on drug pharmacokinetics and drug effect and the need for separate clinical trials and pharmacological studies of drugs in pediatric patient populations • The chloramphenicol-induced gray baby syndrome is an example of the potential dangers inherent in treating newborns based on dosing recommendations in adults

INTRODUCTION… • In late 1950s case reports of unexplained deaths in newborns who were receiving chloramphenicol appeared • These deaths led to a controlled clinical trial of chloramphenicol therapy in premature newborns • High concentrations of chloramphenicol and its metabolites accumulated in newborns presumably accounted for the severe toxicity • This accumulation of drug on a dosing regimen that is tolerable in adults resulted from the reduced capacity of newborns to metabolize chloramphenicol by glucuronide conjugation • The rate of chloramphenicol metabolism was found to be highly age dependent and the half-life was 26 hours in the newborns, 10 hours in the infants, and 4 hours in the older children

INTRODUCTION… • Therapeutic tragedies such as this could be avoided by performing pediatric pharmacological studies during the drug development process • Zidovudine is eliminated in adults primarily by glucuronide conjugation, suggesting that newborns may have a reduced capacity to eliminate the drug • Unlike chloramphenicol, prior to widespread administration of zidovudine to newborns and infants born to HIV infected mothers, the pharmacology and safety of the drug were carefully studied in this population and age-specific dosing guidelines were developed

GENERAL CONSIDERATIONS • Infancy and childhood is a period of rapid growth and development of organ systems and so careful administration of drugs should be ensured • Term infants undergo rapid physiologic changes in total body water and in renal and hepatic function during the first few days of life • CNS maturation with completion of myelination occurs in the infant and toddler age group • During the age of 1-12 years almost 60% drop in extra cellular volume • Dosage is adjusted based on pharmacokinetic data of a given age group for the desired response, but considering each individual’s drug handling capacity is often the most rational approach

ABSORPTION • Gastric pH is6-8 at birth, but drops to pH 1–3 within 24hours of birth • Gastric acid secretion then declines (Achlorhydria) during 8–30 days, and does not approach adult values until approximately 3 years of age • This lower level of gastric acid secretion contributes to the increased bioavailability of acid-labile drugs in neonates compared to older children and adults (E.g.: Penicillin G, Ampicillin)

ABSORPTION… • Gastric emptying is delayed (upto 6 – 8 hours) and irregular in the neonate and infant, but approaches adult values by 6–8 months of age • Intestinal motility (peristalsis) is also irregular, unpredictable and only partially dependent on feeding patterns in newborn until 1 year • In newborns, decreased GI motility can delay drug absorption and result in lower peak plasma drug concentrations, but does not alter the fraction of drug absorbed for most drugs • In older infants and children, GI transit time may be increased

ABSORPTION… • Premature infants and neonates have diminished bile acid pool and biliary function develops during the first month of life • This may have influence on drugs undergo enterohepatic circulation after conjugation with glucuronic acid • Enzymatic activity in the GI tract, specifically, a 7 fold increase in the capacity of β - glucuronidase andUDP – glucuronyl transferase in the neonatal gut • The ratio of absorptive surface area to BSA is greater in infants and children than in adults • Although pancreatic enzymeexcretion is low in neonates, malabsorption does not occur and no effect on drug absorption has been observed

ABSORPTION… • The newborn intestine is colonized with bacteria within days of birth, but the spectrum of bacterial flora may change over the first few years of life • The patterns and extent of colonization depend on age, type of delivery, type of feeding, and concurrent drug therapy • Compared to adults, the capacity of intestinal bacterial flora to inactivate orally administered drug is less and thereby bioavailability is increased in infants less than 2 years old • Drug absorbed by the oral route is erratic in the newborn baby of any gestation • Thus it is usual to give many drugs by the iv/im route to ensure maximum BA

AGE DEPENDENT PHYSIOLOGIC VARIABLES INFLUENCING ORAL DRUG ABSORPTION AS COMPARED TO ADULTS

ABSORPTION… • Absorption following i.m. administration depends mainly on the regional blood flow which may differ among specific muscles • In neonates, the i.m. absorption pattern may considerably change during the first 2 weeks of life • Reduction in absorption rate of intramuscularly administered Digoxin and Gentamycin have been reported in neonates • Increased skin permeation found in neonates and infants results in increased systemic absorption

SUMMARY OF DRUG ABSORPTION IN PEDIATRIC PATIENTS

POSSIBLE PHARMACOKINETIC CONSEQUENCES

RELATIVE GASTROINTESTINAL ABSORPTIONOF SELECTED DRUGS IN INFANTS AND ADULTS

DISTRIBUTION • Total body water accounts for a larger fraction of body weight in newborns than in older children and adults • There is also a larger fraction of extracellular water at birth

DISTRIBUTION • As a result of this, the apparent distribution volume of the water-soluble drug is greater in newborns and infants than in adults when normalized to body weight or surface area (E.g.: Sulfisoxazole) • Total body water decrease throughout the first year and shift predominantly from extra cellular to intracellular fluid • Dosage adjustment has to be done to drugs that are highly water soluble like Gentamycin to avoid ADR • Few lipophilic drugs have comparatively a large Vd despite of lower adipose tissue (because of higher proportion of body fat than adults and high affinity of these lipid sites) e.g.: Diazepam • Large interpatient variability in Vd due to varied nature of maturation

DISTRIBUTION • Serum albumin, α-1 acid glycoprotein, and total protein concentrations are lower at birth and during early infancy • Total proteins and plasma protein binding reach adult values at about 1 year of age • The reduced plasma protein binding in newborns is due to the concurrence of several factors such as • Reduced total plasma protein concentrations associated with a qualitative difference in plasma protein content • Fetal albumin has lower affinity for drugs and a lower level of γ-globulin and lipoproteins • A condition of relative hypoxaemia associated with a lower blood pH • A high plasma concentration of free fatty acids and unconjugated bilirubin which may compete with acidic drugs at albumin binding sites • The possible presence of ‘competitive binding’ substances of maternal origin

DISTRIBUTION • The ratio of bound drug concentration (B) to free drug concentration (F) can be written in terms of the number of binding sites (n), the molar protein concentration (P), and the affinity constant (KA), as shown in Equation • For most drugs in their therapeutic range, the product of F and KA is much less than 1; therefore, the fraction unbound is drug concentration independent (ie, linear binding) • Hence, the above equation could be written as follows for the infant and adult, respectively

DISTRIBUTION • If the intrinsic properties of the protein (n and KA) are assumed to remain constant with age, adult equation may be rearranged to solve for a common KA and subsequently substituted into infant equation results in • From a pharmacokinetics perspective, the fraction unbound is more valuable and more frequently reported than is B/F ratios • Fraction unbound drug in the plasma ƒu is defined as the ratio of F to total drug concentration is the sum of F and B

DISTRIBUTION • Based on the above two equations, a relationship can be derived that predicts the fraction unbound for infants in terms of the ratio of the binding protein concentration (infant to adult) and the adult fraction unbound • As the ratio of abundance of binding proteins approaches unity, the fraction unbound in infants approaches adult values • The use of adult intrinsic clearance values may need to be adjusted for differences in binding for highly bound drugs in cases where the plasma protein concentration is significantly lower in infants

PLASMA PROTEIN BINDING AND DRUG DISTRIBUTION (SUMMARY)

METABOLISM • At birth, majority of the metabolic enzyme systems are either absent or present in considerably reduced amounts (20 % - 70 %) compared to adults (Exemptions: Sulphate conjugation is more) • Glucuronitation is very less. Therefore, chloramphenicol is not bound extensively and so no / poor elimination (metabolism) results accumulation of chloramphenicol that leads to Gray baby syndrome • Caffeine in children may have half life of even 5 days but, in adults it is 4 hours • So, drugs that are extensively metabolized by liver should be administered cautiously(caffeine, lidocaine, chloramphenicol) • A reduced capacity to dispose of drugs is constantly observed during the first 156 days of life

METABOLISM… • In most cases such a stage of reduced metabolic degradation is then followed by a dramatic increase in the metabolic rate of mainly phase I reactions • The increased metabolic disposition rate is usually very evident from 2-3months up to 2-3 years of age • Then values tend to decline gradually to reach those of adults after puberty • Hormonal changes occurring during puberty can also affect drug disposition • Another important aspect of drug metabolism is dose – dependent or enzyme capacity limited drug elimination that is important for all age groups

DRUG METABOLISM IN NEONATE, INFANT AND CHILD (SUMMARY)

EXCRETION • Renal function is significantly lower in infants and small children when compared to adults, because of variation in • Renal plasma blood flow • GFR • Secretion • Reabsorption • At birth, kidney blood flow is characterized by increased vascular resistance and a preferential intrarenal flow away from the outer kidney cortex • After 2-3 days of extra uterine life the GFR may be 8 -20 ml/min • GFR is approximately 40 ml/min/1.73 Sq. m in the term neonate and gradually increases to adult values by three years of age

EXCRETION… • Passive tubular reabsorption may be reduced in the infant and neonate • Therefore , dosage must be individualized with a careful assessment of therapeutic effect • Renal drug elimination is the primary route for antimicrobial agents which are the most commonly used drugs in children(β- lactam antibodies, amino glycosides)

RENAL FUNCTION IN NEONATE, INFANT AND CHILD (SUMMARY)

ISSUES IN THERAPEUTICS • Sampling blood is both difficult & questionable • Alternative source to be considered (saliva, urine) • Estimation from urinary samples involve either • Sigma Minus Method log (Xuα– Xut) = log Xuα-Kt / 2.303 Or • Excretionrate plot log (∆Xu/ ∆t) = log Ke X0/ 2.303 • Many drugs are often estimated by this method (paracetamol, gentamycin) • For drugs that achieve saturation kinetics rate of drug administration can be calculated using “Michaelis – Menton equation D/t = Vmax * C/Km + C

DOSAGE • In selecting a method of dosage calculation therapeutic index of the drug should be considered • For narrow therapeutic index drugs, dosing must be based on the calculated body surface area (recommendations are quoted in per square meter area) • Dosage adjustments based on TDM and nomograms in single and drug combination situations are possible • However, wide variations in Vd and CL exist

FACTORS TO BE CONSIDERED WHEN SELECTING A DRUG DOSAGE REGIMEN OR ROUTE OF ADMINISTRATION FOR A CHILD PATIENT • Age / Weight / Body surface area • Dose / Dose interval • ROA • Formulation / Preparation • PK • Interactions • ADR • Counseling and compliance aids • Legal considerations

SOME USEFUL FORMULAS TO CALCULATE CHILD DOSE • Clark’s rule: Infant dose = (BW infant / BW adult) * Adult dose • Based on BSA: Infant dose (if Vd < 0.3 L/Kg) = (BSA/1.73) * A.D Infant dose (if Vd≥ 0.3 L/Kg) = (BSA/70) * A.D BSA neonate = 0.224265 * BW0.5378 *Ht0.3964 BSA infant = 0.007184 * BW0.425 *Ht0.725

MONITORING • Monitoring drug concentration from serum or the biological fluids is useful if desired effect is not obtained • Monitoring also helps to avoid ADR which may sometimes be fatal to the children

• More by User

PALLIATIVE CARE IN PEDIATRIC PATIENTS

PALLIATIVE CARE IN PEDIATRIC PATIENTS. AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF NEURO-ONCOLOGY AND CHILDHOOD CANCER DIVISION OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI COMPREHENSIVE CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL. INTRODUCTION.

1.87k views • 47 slides

Drug use in Pediatric

752 views • 35 slides

Cardiac CT in Pediatric Patients

Cardiac CT in Pediatric Patients. Marilyn J. Siegel, M.D. Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, MO. USA. FDA Questions: Contrast-enhanced Pediatric Cardiac CT. Indications for CT Impact of CT on diagnosis &amp; treatment

1.39k views • 49 slides

Gastrointestinal Disorders in Pediatric Patients

Gastrointestinal Disorders in Pediatric Patients. Revised, Summer 2009. Cleft Lip and Cleft Palate. Etiology- Failure of maxillary and median nasal processes to fuse during embryonic development Remember the psycho-social implications for these children and families . Assessment.

1.44k views • 48 slides

Pediatric and Geriatric Dosing for LDN

Pediatric and Geriatric Dosing for LDN. Deanna Windham, D.O. Chronic Caregiver Status. Millions of people and families impacted nationwide Increased rates of illness and job challenges for caregivers Social impact kids develop less social skills adults withdraw from social interactions.

359 views • 13 slides

Drug Therapy in the Pediatric Patient

Drug Therapy in the Pediatric Patient. Jan Bazner-Chandler RN, MSN, CNS, CPNP. Safe Drug Administration. Administration of drugs during the first year of life can be a challenge due to rapid changes in body size, body composition, and organ function. . Historical Perspective .

830 views • 50 slides

Antifungal Dosing and Therapeutic Drug Monitoring

Antifungal Dosing and Therapeutic Drug Monitoring. Andrew J. Ullmann , MD, FIDSA Julius- Maximilians - Universität Department of Internal Medicine II Division of Infectious Diseases Würzburg , Germany [email protected]. Disclosure of Potential Conflicts of Interest: .

976 views • 35 slides

Drug Dosing in Special Populations

Drug Dosing in Special Populations. Henny Lucida, PhD, Apt. Patient conditions that may altered the dosing of most drugs:. Renal or hepatic disease, may decrease the elimination or metabolism of the majority of drugs and change the clearance

1.48k views • 38 slides

Pediatric Drug Therapy

Pediatric Drug Therapy. Cortez,Anne ; Cortez,Feliza ; Cristi , Frances; Cruz,Denise ; Cruz,Ferdinand ; Cruz,Karen ; Cruz,Belle ; Cruz,Mary ; Cua,Ronald. Pharmacogenetics. Role of genetic factors in drug disposition and response

796 views • 34 slides

Drug Therapy in Pediatric Patients

Chapter 10. Drug Therapy in Pediatric Patients. Drug Therapy in Pediatric Patients. Pediatrics includes all patients younger than age 16 Pediatric populations have six groups Premature infants (less than 36 weeks gestation) Full-term infants (36 to 40 weeks) Neonates (first 4 weeks)

1.08k views • 7 slides

Thrombotic complications in pediatric patients

Thrombotic complications in pediatric patients. בן 15 אושפז במחלקת ילדים ב-5.96 עקב דלקת ריאות. באשפוז התקבלה אנמנזה של מאורע פתאומי של הפרעה בדיבור , מלווה ברעד כשנתיים לפניכן. מאז המאורע התרשמו ההורים מירידה בתפקוד עם קשיים בריכוז והילד, שהיה עד אז תלמיד טוב, הפסיק ללמוד.

760 views • 61 slides

Novel Drug Delivery in Pediatric Medulloblastoma

Novel Drug Delivery in Pediatric Medulloblastoma. Group 37 – Chris Peng (Presenter), Arvin Soepriatna , Blessan Seb astian Client: Mr. Mike Sabo, Pulse Therapeutics, Inc. BME 401, Prof. Anastasio 10/2/2013. Background.

314 views • 18 slides

Novel Drug Delivery in Pediatric Medulloblastoma. Group 37 – Arvin Soepriatna (Presenter), Chris Peng , Blessan Sebastian Client: Mr. Mike Sabo, Pulse Therapeutics, Inc. BME 401, Prof. Anastasio 10/28/2013. Need.

383 views • 19 slides

FAST Exam in pediatric patients

FAST Exam in pediatric patients. Evidence in the ED March 5, 2014 Sarah Cavallaro PGY-3. Introduction. The role of the FAST exam in Pediatric Trauma is unclear Review 4 studies that set the stage for current thinking Share my thoughts on how I wish these were done

560 views • 19 slides

Soft Computing Methods for Drug Dosing in Renal Anemia

Soft Computing Methods for Drug Dosing in Renal Anemia. Adam E. Gaweda Kidney Disease Program University of Louisville Louisville, KY http://kdp.louisville.edu. Overview. Anemia in End Stage Renal Disease Soft Computing in Anemia Treatment Intelligent modeling and control for drug dosing

411 views • 29 slides

Olmesartan medoxomil dosing schedule justification in pediatric hypertensive patients

Olmesartan medoxomil dosing schedule justification in pediatric hypertensive patients. Authors: SaeHeum Song* , Raymond Miller, Daniel Salazar. Daiichi Sankyo Pharma Development, Edison, NJ, USA. Objectives.

214 views • 1 slides

From Population to Individual Drug Dosing in Chronic Illness

From Population to Individual Drug Dosing in Chronic Illness. Intelligent Control for Management of Renal Anemia. Adam E Gaweda University of Louisville Department of Medicine. Challenges in Dynamic Treatment Regimes and Multistage Decision-Making. Overview. Anemia management

354 views • 23 slides

ANAESTHETIC IMPLICATIONS IN PEDIATRIC PATIENTS

ANAESTHETIC IMPLICATIONS IN PEDIATRIC PATIENTS. Dr Vishawjeet Singh Moderator Dr Jyoti Pathania. PREOPERATIVE PREPARATION A– In addition to routine pre- anaesthetic evaluation, the following points should be stressed: 1- gestational age at birth- extent of prematurity.

781 views • 54 slides

Drug Dosing in PCRRT

Drug Dosing in PCRRT. Deb Pasko, Pharm.D Pharmacy Clinical Specialist, PICU University of Michigan Health System. CRRT Solute Removal. Lots of things removed by CRRT! Drugs, nutrients… FD&amp;C Blue dye #1… Crit Care Med, Mar 2002. Dialysate is used (lactated Ringers, PD solution, etc)

747 views • 47 slides

Gastrointestinal Disorders in Pediatric Patients. Marlene Meador RN, MSN Fall 2006. Cleft Lip and Cleft Palate. Etiology- Failure of maxillary and median nasal processes to fuse during embryonic development Remember the psycho-social implications for these children and families. photos.

688 views • 55 slides

DRUG DOSING IN ELDERLY

DRUG DOSING IN ELDERLY. K.P. ARUN LECTURER DEPARTMENT OF PHARMACY PRACTICE JSS COLLEGE OF PHARMACY OOTY. INTRODUCTION Ever increasing population of aged people (&gt;65yrs)

1.34k views • 17 slides

651 views • 61 slides

Slide Set—Introduction to Tuberculosis

Return to Slide Sets Main Menu

This introduction to TB slide set is meant to be a tool for people who are not familiar with TB. It provides a basic overview of TB using plain language and visual aids. This slide set is intended for a general public audience.

• Download complete set (43 slides) in Power Point format [PPT – 60MB]
• Slide Set Narrative [PDF – 129KB]

To receive email updates about this page, enter your email address:

Exit Notification / Disclaimer Policy

• The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
• Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
• You will be subject to the destination website's privacy policy when you follow the link.
• CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.

• Preferences

Pharmacokinetics: Drug Distribution - PowerPoint PPT Presentation

Pharmacokinetics: Drug Distribution

Topic 3 pharmacokinetics: drug distribution 713 311 principles of veterinary pharmacology dr. korawuth punareewattana faculty of veterinary medicine, khon kaen university – powerpoint ppt presentation.

• Factors affecting drug distribution
• Volume of distribution
• Phase of distribution
• Protein binding
• Drug reservoir
• Drug redistribution
• Drug distribution
• is a step which describes the reversible transfer of drug from one location to another within the body.
• Distribution is influenced by
• a) Blood flow to target tissues
• b) Ability of drug to exit blood vessels
• typical capillary - no barrier
• blood-brain barrier tight junctions between endothelial cells (only lipid soluble)
• placental barrier - only lipid soluble pass freely
• c) Ability to enter cells
• must be lipid soluble, or have transporter
• most drugs act at receptors on cell surface (do not enter)
• Factors ? rate of distribution
• Membrane permeability
• Blood perfusion
• Factors ? extend of distribution (how much)
• Lipid solubility
• Plasma protein binding
• Tissue protein binding
• Elimination processes
• A measure of the tendency of a drug to move out of the blood plasma to some other site.
• Or A measure of extend of distribution
• Plasma reservoirs
• a1-acid glycoprotein
• Tissue or Cellular reservoirs
• Adipose reservoir
• Bone reservoir
• Transcellular reservoir
• GI tract reservoir
• not only affects the activity of the drug (bound inactive)
• But also can influence its distribution from one compartment to another.
• This is particularly true with respect to glomerular filtration and passive transport.
• Free Protein ? Bound Drug Drug
• albumin- primarily for acidic drugs
• - for basic drugs
• Lipoproteins
• - for some drugs
• The fraction of total drug in plasma that is bound is determined by
• the drug concentration,
• its affinity for the binding sites, and
• the number of binding sites.

PowerShow.com is a leading presentation sharing website. It has millions of presentations already uploaded and available with 1,000s more being uploaded by its users every day. Whatever your area of interest, here you’ll be able to find and view presentations you’ll love and possibly download. And, best of all, it is completely free and easy to use.

You might even have a presentation you’d like to share with others. If so, just upload it to PowerShow.com. We’ll convert it to an HTML5 slideshow that includes all the media types you’ve already added: audio, video, music, pictures, animations and transition effects. Then you can share it with your target audience as well as PowerShow.com’s millions of monthly visitors. And, again, it’s all free.

About the Developers

PowerShow.com is brought to you by  CrystalGraphics , the award-winning developer and market-leading publisher of rich-media enhancement products for presentations. Our product offerings include millions of PowerPoint templates, diagrams, animated 3D characters and more.